Jeffrey Pu
Hematology & Oncology · Hershey, PANPI 1831399708
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AstraZeneca at 31.7% of the total. Reporting peaked in 2019 at $35,110 and has fallen 99.2% since, to $281 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $876.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$33K
- F. Hoffmann-la Roche AG$17K
- Astellas Pharma US Inc$16K
- Jazz Pharmaceuticals Inc.$7K
- E.r. Squibb & Sons, L.L.C.$6K
- Incyte Corporation$6K
- plus $18K from 12 others
Across 146 payments — averaging $1060.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$36K
- Genentech, Inc.$34K
- Karyopharm Therapeutics Inc.$28K
- Pfizer$20K
- Bristol Myers Squibb$19K
- AstraZeneca$9K
- plus $9K from 2 others
What the payments were for
- Consulting fees$54,08552%
- Speaking & faculty fees$24,13923%
- Travel & lodging$20,31920%
- Food & beverage$4,7155%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 32 | $32,729 |
| F. Hoffmann-la Roche AG | 4 | $17,359 |
| Astellas Pharma US Inc | 18 | $16,397 |
| Jazz Pharmaceuticals Inc. | 13 | $6,968 |
| E.r. Squibb & Sons, L.L.C. | 6 | $6,333 |
| Incyte Corporation | 10 | $5,758 |
| Bristol Myers Squibb | 13 | $5,316 |
| Novartis | 3 | $4,599 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,058 |
| Rigel Pharmaceuticals, Inc. | 2 | $2,395 |
| Gilead(2 entities) | 7 | $675 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Servier Pharmaceuticals LLC | 1 | $140 |
| Stemline Therapeutics Inc. | 1 | $131 |
| TG Therapeutics, Inc. | 1 | $120 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $99 |
| Karyopharm Therapeutics Inc. | 1 | $75 |
| Apellis Pharmaceuticals, Inc. | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,373 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Hershey
- Kevin RakszawskiHershey$237K
- Chandra BelaniHershey$149K
- Cristina TruicaHershey$102K
- David NguyenHershey$81K
- Joseph DrabickHershey$53K
- Patrick MaHershey$42K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.